Advertisement

Topics

Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer’s Association International Conference

08:30 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for Precision Medicine Approach for ALZ-801 Alzheon, Inc., a clinical-stage biopharmaceutical compan...

Other Sources for this Article

The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer’s Association International Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...